Biomarin Pharmaceutical Inc (BMRN)

Pharmaceutical Preparations

Latest Price

$60.00

TTM P/E

153.85

Normalized P/E

46.80

Div Yield

Book Value

32.71

P/B Ratio

1.83

Valuation metrics

EPS: $1.80

Book value / share: $31.65

Formula: √(22.5 × EPS × BVPS)

Graham Number

$35.80

40% downside

Norm. op. income: $150M (median of 7yr)

Tax rate: 16%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$13.34

78% downside

Base FCF: $209M (median of recent 5yr)

Growth: 19%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$60.81

+1% upside

EPS: $1.80

Target P/E: 47×

Formula: EPS × P/E

P/E Fair Value

$84.60

+41% upside

99.9% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	20.45M	$1.17B	10.56%	+626.9K	2026-06-30
Dodge & Cox	14.84M	$849.0M	7.67%	+283.2K	2026-06-30
Primecap Management Co	14.19M	$811.0M	7.33%	-3.8K	2026-06-30
Vanguard Capital Management LLC	8.74M	$500.0M	4.52%	+100.5K	2026-06-30
Vanguard Portfolio Management LLC	8.65M	$494.0M	4.47%	+350.2K	2026-06-30
Norges Bank	8.21M	$469.0M	4.24%	+676.9K	2026-06-30
State Street Corp	7.80M	$446.0M	4.03%	+505.9K	2026-06-30
Viking Global Investors LP	7.62M	$435.0M	3.94%	+1.58M	2026-06-30
Vestal Point Capital, LP	6.03M	$344.0M	3.11%	+2.45M	2026-06-30
AQR Capital Management LLC	5.70M	$322.0M	2.94%	-1.98M	2026-06-30